Tags

Type your tag names separated by a space and hit enter

Development of type I gastric carcinoid in patients with chronic atrophic gastritis.
Aliment Pharmacol Ther. 2011 Jun; 33(12):1361-9.AP

Abstract

BACKGROUND

Long-term observational studies assessing the incidence of type I gastric carcinoid (typeIGC) in patients with chronic atrophic gastritis are few.

AIM

To evaluate the occurrence of typeIGC at diagnosis and during follow-up and to identify patient features associated with the presence of typeIGC in a cohort of chronic atrophic gastritis patients.

METHODS

Three hundred and sixty-seven chronic atrophic gastritis patients [245 women, age 54 (18-79) years] underwent regular follow-up by gastroscopy. The incidence of typeIGC was determined in chronic atrophic gastritis patients with at least 2 years of follow-up (n = 214). Baseline clinical and histological features were analysed as factors associated with the presence of typeIGC by univariate analysis.

RESULTS

Type I gastric carcinoid was diagnosed in nine (2.4%) patients at the moment when chronic atrophic gastritis was diagnosed. After 1463 person-years, six patients developed typeIGC with an annual incidence rate (person-year) of 0.4%. Patients with typeIGC had significantly higher levels of gastrin, chromogranin A and more frequently the presence of body polyps and ECL-dysplasia compared with chronic atrophic gastritis patients without typeIGC.

CONCLUSIONS

This cohort study shows that typeIGC is a rare complication in patients with chronic atrophic gastritis, and the presence of body polyps and ECL-dysplasia at gastroscopic/histologic evaluation is strongly associated with the presence of typeIGC.

Authors+Show Affiliations

Dipartimento Medico-Chirurgico di Scienze Cliniche, Tecnobiomediche e Medicina Traslazionale, Sant'Andrea Hospital, School of Medicine, University Sapienza, Rome, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21492197

Citation

Vannella, L, et al. "Development of Type I Gastric Carcinoid in Patients With Chronic Atrophic Gastritis." Alimentary Pharmacology & Therapeutics, vol. 33, no. 12, 2011, pp. 1361-9.
Vannella L, Sbrozzi-Vanni A, Lahner E, et al. Development of type I gastric carcinoid in patients with chronic atrophic gastritis. Aliment Pharmacol Ther. 2011;33(12):1361-9.
Vannella, L., Sbrozzi-Vanni, A., Lahner, E., Bordi, C., Pilozzi, E., Corleto, V. D., Osborn, J. F., Delle Fave, G., & Annibale, B. (2011). Development of type I gastric carcinoid in patients with chronic atrophic gastritis. Alimentary Pharmacology & Therapeutics, 33(12), 1361-9. https://doi.org/10.1111/j.1365-2036.2011.04659.x
Vannella L, et al. Development of Type I Gastric Carcinoid in Patients With Chronic Atrophic Gastritis. Aliment Pharmacol Ther. 2011;33(12):1361-9. PubMed PMID: 21492197.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Development of type I gastric carcinoid in patients with chronic atrophic gastritis. AU - Vannella,L, AU - Sbrozzi-Vanni,A, AU - Lahner,E, AU - Bordi,C, AU - Pilozzi,E, AU - Corleto,V D, AU - Osborn,J F, AU - Delle Fave,G, AU - Annibale,B, Y1 - 2011/04/15/ PY - 2011/4/16/entrez PY - 2011/4/16/pubmed PY - 2011/9/29/medline SP - 1361 EP - 9 JF - Alimentary pharmacology & therapeutics JO - Aliment Pharmacol Ther VL - 33 IS - 12 N2 - BACKGROUND: Long-term observational studies assessing the incidence of type I gastric carcinoid (typeIGC) in patients with chronic atrophic gastritis are few. AIM: To evaluate the occurrence of typeIGC at diagnosis and during follow-up and to identify patient features associated with the presence of typeIGC in a cohort of chronic atrophic gastritis patients. METHODS: Three hundred and sixty-seven chronic atrophic gastritis patients [245 women, age 54 (18-79) years] underwent regular follow-up by gastroscopy. The incidence of typeIGC was determined in chronic atrophic gastritis patients with at least 2 years of follow-up (n = 214). Baseline clinical and histological features were analysed as factors associated with the presence of typeIGC by univariate analysis. RESULTS: Type I gastric carcinoid was diagnosed in nine (2.4%) patients at the moment when chronic atrophic gastritis was diagnosed. After 1463 person-years, six patients developed typeIGC with an annual incidence rate (person-year) of 0.4%. Patients with typeIGC had significantly higher levels of gastrin, chromogranin A and more frequently the presence of body polyps and ECL-dysplasia compared with chronic atrophic gastritis patients without typeIGC. CONCLUSIONS: This cohort study shows that typeIGC is a rare complication in patients with chronic atrophic gastritis, and the presence of body polyps and ECL-dysplasia at gastroscopic/histologic evaluation is strongly associated with the presence of typeIGC. SN - 1365-2036 UR - https://www.unboundmedicine.com/medline/citation/21492197/Development_of_type_I_gastric_carcinoid_in_patients_with_chronic_atrophic_gastritis_ L2 - https://doi.org/10.1111/j.1365-2036.2011.04659.x DB - PRIME DP - Unbound Medicine ER -